Back to the main directory
Company Analysis / Equity
- Challenger’s Disappointing Fiscal 2018 Results Prompt a Modest FVE Reduction to AUD 12.60 by Morningstar
- I.CERAM. RN S1 2018. Résultat S1 2018 en ligne (=) by MidCap Partners
- Grandvision: CMD Feedback - 2023 Targets: Continuation and... Acceleration by Bryan Garnier
- Moving Tobacco Trend Ratings to Negative, but Market Is Too Pessimistic on Our Picks by Morningstar
- CA + RN S1 2018 - CA +2,6% / REX +40% - Opinion : Achat - Objectif : 1,56 € - Potentiel +67,4% by GreenSome Finance
- Alten: H1 2018 results above expectations, free cash flow down, outlook reiterated by Bryan Garnier
- GENEURO: (BUY, Fair Value Under Review) by Bryan Garnier
- Moving Tobacco Trend Ratings to Negative, but Market Is Too Pessimistic on Our Picks by Morningstar
- Morningstar | Moving Tobacco Trend Ratings to Negative, but Market Is Too Pessimistic on Our Picks by Morningstar
- Morningstar | Moving Tobacco Trend Ratings to Negative, but Market Is Too Pessimistic on Our Picks by Morningstar
- Morningstar | Moving Tobacco Trend Ratings to Negative, but Market Is Too Pessimistic on Our Picks by Morningstar
- While solid results and promotion of CFO Yoshida encourage the market, we view shares as overvalued. by Morningstar
- The Market Today - 21 September 2018 by Vetiva Capital Management
- Event update: Aurobindo Pharma (Outperformer) - Sandoz business acquisition – Value accretive by IDFC Securities
- We expect profitability to recover following the move to everyday low pricing at the Red Sheds. by Morningstar
- Morningstar | We expect profitability to recover following the move to everyday low pricing at the Red Sheds. by Morningstar
- Management Speak: Bharat Electronics (Outperformer) - Margin rationalisation to see limited impact by IDFC Securities
- Sector update: Power Utilities; Stressed Assets – The beginning of the end by IDFC Securities
- Sector update: Alcoholic Beverages - Interaction with Allied Blenders and Distillers by IDFC Securities
- Initiating coverage: Aarti Industries (Outperformer) - Entering into a new orbit by IDFC Securities
- Event update: Financials - IL&FS – Assessing risks for lenders by IDFC Securities
- Initiating coverage: Dr Lal PathLabs (Outperformer) - Right Diagnosis by IDFC Securities
- GROUPE AURES. Net result H1 2018. Phenomenal (+) by MidCap Partners
- IPSEN. CHMP’s Positive Opinion of Cabometyx (+) by MidCap Partners
- LE BELIER. Resistant fundamentals (=) by MidCap Partners